LLM 2021 | Antibody-drug conjugates and checkpoint inhibitors in Hodgkin lymphoma
Jonathan Friedberg
• 21 Oct 2021
Jonathan Friedberg, MD MMSc, Wilmot Cancer Center, University of Rochester, Rochester, NY, comments on antibody-drug conjugates and checkpoint inhibitors in the treatment of relapsed Hodgkin lymphoma, whose efficacy supports their use early in the disease, including after the first relapse or as part of upfront therapy. Looking into the future, interesting preliminary results suggest both drug types could be used in combination, for which confirmatory trials are planned. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
